391 related articles for article (PubMed ID: 16111462)
1. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
2. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
3. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
4. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
8. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
10. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
11. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
[TBL] [Abstract][Full Text] [Related]
14. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
16. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
17. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
18. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
19. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
Yri OE; Bjoro T; Fossa SD
Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
[TBL] [Abstract][Full Text] [Related]
20. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
